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Abstract 
Rituximab is a biologic agent that is usually well tolerated. With its increasing use for a 
myriad of rheumatologic and immunologic conditions, post-marketing surveillance has 
revealed more side effects. Systemic inflammatory response syndrome associated with 
cytokine release syndrome (CRS) is a very rare entity associated with the use of rituximab 
and carries a very high morbidity and case fatality rate. Cases of CRS reported within the 
literature are of patients with a very high tumor burden leading to a catastrophic cascade of 
events. We report the case of a patient having post-transplant lymphoproliferative disorder 
who died of fatal lactic acidosis and CRS within 24 h of receiving rituximab. Understanding 
the pathophysiology of such cases and identifying patients at risk may help to possibly avert 
this life-threatening complication. 
 
Case Presentation 
A 72-year-old Caucasian man with a past medical history notable for orthotopic heart 
transplantation for non-ischemic cardiomyopathy, Type 2 diabetes mellitus, chronic renal 
insufficiency, idiopathic thrombocytopenic purpura, and cryptogenic cirrhosis was initially admitted 
to the Intensive Care Unit for refractory acute kidney injury in the setting of newly diagnosed 
post-transplant lymphoproliferative disorder (PTLD). 
He initially went to a local hospital for abdominal pain where his blood work revealed acute 
kidney injury superimposed on his chronic renal insufficiency. Imaging showed unilateral 
hydronephrosis and a renal stone at the ureterovesical junction. Hence, he had a ureteral stent placed. 
However, his renal function did not improve. 
During the same admission, the patient was found to have several subcutaneous violet nodules 
over the abdomen (fig. 1). Biopsy of these lesions showed diffuse large B-cell lymphoma, after which 
he was transferred to a tertiary care center for further management and care.  
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Further evaluation showed CD20+ cells on bone marrow biopsy. A computerized tomography scan 
of his chest, abdomen and pelvis showed evidence of new extensive omental, peritoneal and 
mesenteric lymph node involvement and pulmonary nodules depicting severe PTLD. He was initially 
started on high-dose prednisone for lymphoma, which was attributed to PTLD. 
Given worsening of his renal function in the setting of hypotension and anasarca, the patient was 
started on continuous veno-venous hemodialysis in the Intensive Care Unit. He was also empirically 
started on treatment with broad-spectrum antibiotics and anti-fungals, and was pressor-dependent. 
Infectious workup was negative, and a diagnostic paracentesis revealed lymphocytic predominant 
exudate but negative Gram stain and cultures. The patient remained stable on continuous 
veno-venous hemodialysis with a stable pressor requirement for several days. 
Given the CD20 positivity on the bone marrow biopsy and a Ki-67 of more than 90% (representing 
the aggressive nature of the PTLD) the patient was started on rituximab. He tolerated the infusion 
without any immediate complications. However, within 18 h of the first rituximab infusion, he 
developed severe worsening abdominal pain, profound refractory lactic acidosis, increasing pressor 
requirements and respiratory failure requiring emergent intubation. He also had multiple episodes of 
bradycardic arrests due to metabolic derangements. Labs eventually revealed disseminated 
intravascular coagulation. The patient eventually developed hemoptysis and bronchoscopy revealed 
blood but no clots. Hypotension became refractory to pressors and the patient eventually died of 
asystole. During his worsening clinical condition, there was no electrical or biochemical evidence of a 
myocardial infarction. Imaging studies also failed to demonstrate any bowel perforation. There was 
no evidence of active tumor lysis demonstrated by stable lactate dehydrogenase and uric acid levels. 
The patient’s death was attributed to severe systemic inflammatory response syndrome (SIRS) versus 
cytokine release syndrome (CRS) leading to shock and lactic acidosis. 
Severe lactic acidosis may be related to the effects of the rapid destruction of tumor cells by 
rituximab (but not as an effect of the drug itself) leading to cytokine release from these cells, causing 
hypoperfusion, hypotension and shock. Unfortunately, the therapy is supportive and carries a high 
morbidity and mortality. 
In the following, we will provide a discussion on along with a review of cases of CRS associated 
with the use of rituximab.  
Discussion 
Rituximab is a monoclonal antibody against the B-cell marker CD20 and is used in a 
variety of conditions including lymphoproliferative disorders and autoimmune 
diseases [1–3]. Rituximab is usually well tolerated. However, with its increasing 
prolonged as well as widespread use for multiple conditions including refractory 
idiopathic thrombocytopenic purpura, refractory thrombotic thrombocytopenic 
purpura, and post-traumatic lymphoproliferative disorder among others, 
post-marketing surveillance has resulted in increasing identification of rare side effects 
[4, 5]. 
The side effects of rituximab are reported based on the grading system for reporting 
adverse effects from chemotherapy (CTCAE: Common Terminology Criteria for Adverse 
Events Version 4.0); Grade 3 and 4 represent moderate to severe adverse events and 
Grade 5 represents fatalities [6]. 
Based on side effects reported from multiple randomized control trials using 
rituximab, the most side effects are of Grade 1 or 2 severity; Grade 3 and 4 are not as 
common, while mortality resulting directly or indirectly after administration of the 
drug is extremely rare [7–9]. A post-marketing surveillance database on rituximab 
indicates a mortality of 0.04–0.07% associated with the drug [10].  
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Severe SIRS and disseminated intravascular coagulation occurring within 24 h of 
administering rituximab have rarely been reported in the literature (table 1). The 
pathophysiology of this reaction is attributed to release of cytokines generally after the 
first administration of rituximab. If uncontrolled, this can lead to SIRS. 
‘The underlying mechanism of cytokine-release syndrome (CRS) is related to 
changes of serum cytokine levels due to rapid injection of the antibody. CRS is 
characterized by an increase of inflammatory cytokines such as IFN-γ, IL-8 and TNF-α 
occurring about 90 min after the first infusion. In severe cases of CRS after rituximab, a 
5 to 10-fold increase in liver enzymes, elevation of D-dimer, lactate dehydrogenase and 
prolongation of protrombin time are also commonly observed’ [10]. 
According to one of the earlier reports on CRS with rituximab, the author noted that 
‘subsequent communication with the manufacturer (Roche Pharmaceuticals, Nutley, 
N.J., USA) revealed that there had been 8 other fatalities possibly related to 
rituximab-induced cytokine release syndrome’ [11]. 
Similarly, in a series of 9 patients with B-cell chronic lymphocytic leukemia, Winkler 
et al. [12] noted a peak rise in serum levels of tumor necrosis factor-α (TNF-α) and 
interleukin-6 (IL-6) in all of their patients. These changes in cytokine levels 
corroborated with clinical symptoms, including fever, chills, nausea, vomiting, 
hypotension, and dyspnea. Patients with lymphocyte counts exceeding 50.0 × 109/l 
experienced a severe CRS which was noted to be statistically significant. 
One hypothesis for early release of cytokines is the agglutination of small 
lymphocytes in the lung, liver and spleen (leukostasis) which has been documented in 
autopsies [12]. Leukostasis in pulmonary vasculature may have contributed to hypoxia 
and respiratory compromise as noted in our patient. Alternatively, cytokine release 
from the apoptotic CD20+ tumor cells and a higher tumor burden in such patients may 
be making them more prone to CRS progressing to SIRS [13]. The rapid turnover of 
tumor cells in such cases may add markedly to the cytokine milieu leading to a 
catastrophic cascade of events [14]. 
CRS, though rare, is associated with considerable mortality. It would be very 
important clinically to identify which subsets of patients are more prone to developing 
the complication. Of note, many of these cases are not reported, nor are the presenting 
features classical [1]. Creating a registry may help in further advancement in terms of 
understanding the pathophysiology and possibly averting the complication. 
Although this is based on case reports and causality is not established, it seems that 
fatal CRS/SIRS appear to occur in patients with a very high tumor burden, as noted in 
our patient as well. Caution needs to be exercised specifically in this subset of patients. 
For example, if patients develop similar but less severe reactions, a reduced dose 
and/or pre-treatment prior to rituximab infusions may be used to reduce the number 
and severity of reactions with subsequent doses [13]. Whether aggressive hydration or 
using anti-inflammatory agents such as steroids prior to administration of rituximab 
reduce the frequency and severity of side effects remains to be studied.  
Case Rep Oncol 2012;5:134–140 
DOI: 10.1159/000337577 
Published online: 
March 20, 2012 
© 2012 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
 
137 
Conclusions 
Rituximab is a biologic agent that is usually well tolerated. With increasing, 
prolonged as well as widespread use for a myriad of conditions, including 
lymphoproliferative disorders and autoimmune conditions, side effects are now being 
reported more often. SIRS (from likely CRS) is a very rare entity associated with the use 
of rituximab and carries a very high morbidity and case fatality rate. Cases reported 
within the literature are of patients with apparently a very high tumor burden leading 
to a catastrophic cascade of events. Creating a registry may help in further 
advancement in terms of understanding the pathophysiology and possibly averting the 
life-threatening complication. 
Acknowledgement 
We are deeply indebted to the family of the patient for allowing us to present his information as a 
case report. 
 
 
  
Case Rep Oncol 2012;5:134–140 
DOI: 10.1159/000337577 
Published online: 
March 20, 2012 
© 2012 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
 
138 
Table 1. Case reports of severe CRS/SIRS 
                      Study  Age/number 
of patients 
Disease   Dose of 
rituximab 
Serious adverse events/clinical course 
                      Seifert et al. [10]  14 years  Pre-B acute 
lymphoblastic leukemia 
and anaplastic 
astrocytoma 
 375 mg/m2  Initially had onset of severe back pain during 
the infusion, followed by SIRS 2 days later 
leading to mortality.  
                      Lim et al. [11]  71 years  Stage I B-cell chronic 
lymphocytic leukemia 
 375 mg/m2  Hypotension/hypoxemia leading to 
cardiovascular collapse 8 h after the first 
infusion of rituximab.  
                      Winkler et al. [12]  9 patients  Chronic lymphocytic 
leukemia 
 375 mg/m2  TNF-α and IL-6 peaked in all of their patients. 
Clinical symptoms included fever, chills, 
nausea, vomiting and hypotension. Rise was 
higher in patients with a higher lymphocyte 
count. No mortalities reported.  
                      Byrd et al. [13]  73 years  Refractory transformed 
B-cell lymphoma 
presented with bulky 
lymphadenopathy 
 375 mg/m2  Patient developed hypoxemia after the first 
infusion, followed by fever, tachycardia, rigors, 
and profuse diaphoresis. Decreased dose and 
pretreatment was done; no reaction noted in 
subsequent doses.  
                      Byrd et al. [13]  5 patients  2 with chronic 
lymphocytic leukemia, 
2 with prolymphocytic 
leukemia and 1 patient 
with diffuse large cell 
lymphoma 
 375 mg/m2  Similar presentation as noted in Byrd et al. [13] 
above after the first infusion; associated with 
this was a rapid decline in the number of tumor 
cells. All patients had a high tumor burden.  
                      Wu et al. [14]  3 patients  Intravascular large 
B-cell lymphoma 
 375 mg/m2  Severe systemic reactions including dyspnea, 
hypoxia, tachycardia and hypotension within 
24 h of their first dose of rituximab. Two 
required endotracheal intubation and 
mechanical ventilation support; one of the 
patients died.  
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Fig. 1. Subcutaneous violet nodules noted over the abdomen of the patient. Biopsy of these lesions 
showed diffuse large B-cell lymphoma. Further evaluation showed CD20+ cells on bone marrow 
biopsy. 
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In	the	article	‘Rituximab	and	Cytokine	Release	Syndrome’	by	Kulkarni	et	al.	[Case	
Rep	 Oncol	 2012;5:134–140]	 an	 error	 occurred.	 In	 the	 discussion	 section	 the	 third	
sentence	must	read:	However,	with	its	increasing	prolonged	as	well	as	widespread	use	
for	 multiple	 conditions	 including	 refractory	 idiopathic	 thrombocytopenic	 purpura,	
refractory	thrombotic	thrombocytopenic	purpura,	and	post‐transplant	lymphoprolif‐
erative	disorder	among	others,	post‐marketing	surveillance	has	resulted	in	increasing	
identification	of	rare	side	effects	[4,	5].	
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